Cypress Asset Management Inc. TX Invests $1.62 Million in Novo Nordisk A/S (NYSE:NVO)

Cypress Asset Management Inc. TX purchased a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 18,072 shares of the company's stock, valued at approximately $1,620,000.

Several other institutional investors have also recently bought and sold shares of NVO. Center for Financial Planning Inc. lifted its stake in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after acquiring an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL raised its stake in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after purchasing an additional 300 shares in the last quarter. Transce3nd LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $33,000. Kelly Lawrence W & Associates Inc. CA bought a new stake in Novo Nordisk A/S during the fourth quarter worth $39,000. Finally, Fourth Dimension Wealth LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $41,000. Institutional investors own 11.54% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Wall Street Zen upgraded Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Finally, Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $135.00.

Novo Nordisk A/S Stock Up 0.7%

Novo Nordisk A/S stock traded up $0.45 during midday trading on Thursday, reaching $69.05. The company's stock had a trading volume of 5,655,270 shares, compared to its average volume of 6,726,512. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market capitalization of $309.86 billion, a P/E ratio of 20.98, a PEG ratio of 0.90 and a beta of 0.65. The stock's 50-day simple moving average is $65.74 and its 200-day simple moving average is $82.29.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion for the quarter. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.